| Naslov: | Effect of biological therapy on symptom burden and functional disability in patients with migraine : a before-and-after analysis |
|---|
| Avtorji: | ID Kalač, Albina (Avtor)
ID Fabjan, Andrej (Avtor)
ID Žibert, Janez (Avtor)
ID Kamenšek, Tina (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (409,79 KB)
MD5: 2BB9C12AD035AC58FC48FC9A85C679BC
 URL - Izvorni URL, za dostop obiščite https://reference-global.com/article/10.2478/sjph-2026-0005
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  NIJZ - Nacionalni inštitut za javno zdravje
 UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Introduction
This study aims to assess the effectiveness of biological therapies in reducing migraine-related symptom
burden and functional disability, including reductions in monthly migraine days, pain intensity, and analgesic
consumption, among patients with migraine in Slovenia.
Methods
This retrospective study analysed 92 adult patients with migraine receiving prophylactic biological treatment
at the University Medical Centre Ljubljana. Average number of monthly migraine days (MMD), average analgesic
consumption, pain intensity (VAS), and functional disability score (MIDAS) were collected before treatment and
after 3 and 12 months. Statistical analysis involved the Friedman test to assess changes over time, followed by
Wilcoxon tests with Bonferroni correction for post hoc comparisons.
Results
83 patients completed 12 months of treatment. Significant reductions (p < 0.001) were observed in MMD (median
10 vs. 2 days), analgesic consumption, VAS scores (median 8 vs. 4), and MIDAS scores after 3 months (median 19
vs. 2), sustained at 12 months. Treatment discontinuation occurred in 9 patients due to inefficacy or side effects.
Most patients tolerated biologics well, with mild adverse effects reported.
Conclusions
Biological therapies significantly reduced migraine-related symptom burden and functional disability, including
decreases in migraine frequency, pain intensity, and analgesic use, in a Slovenian migraine cohort. These findings
support the use of biologics as effective and safe options for migraine prevention in real-world clinical practice. |
|---|
| Ključne besede: | monoclonal antibodies, neurology, disability evaluation, preventive treatment |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum sprejetja članka: | 20.08.2025 |
|---|
| Leto izida: | 2026 |
|---|
| Št. strani: | str. 34-40 |
|---|
| Številčenje: | Vol. 65, no. 1 |
|---|
| PID: | 20.500.12556/DiRROS-30102  |
|---|
| UDK: | 616.857 |
|---|
| ISSN pri članku: | 0351-0026 |
|---|
| DOI: | 10.2478/sjph-2026-0005 |
|---|
| COBISS.SI-ID: | 270641411 |
|---|
| Opomba: | Besedilo v angl.;
|
|---|
| Datum objave v DiRROS: | 15.06.2026 |
|---|
| Število ogledov: | 297 |
|---|
| Število prenosov: | 195 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
